Alamar Biosciences, a portfolio company of Qiming Venture Partners and a global leader in precision proteomics, successfully listed on the NASDAQ Stock Exchange on April 17th, 2026, Beijing Time.

While Cathie Wood’s involvement adds visibility, market sentiment remains mixed on whether ALMR offers sustainable upside at ...

This Clinical Chemistry and Laboratory Medicine review examines a central challenge in precision medicine: whether medical ...

This review examines how high-throughput proteomics is expanding precision medicine by improving biomarker discovery, disease ...

In recent weeks, Thermo Fisher Scientific has announced multiple collaborations and product launches, including data ...

Leinco Technologies, a leader in antibody and protein development, and CellCarta, a global provider of precision medicine laboratory services, are pleased to announce a strategic collaboration aimed ...

Knowing that women are diagnosed with multiple sclerosis (MS) at three times the rate of men, particularly during their 30s ...

Recurrent Florida west coast blooms produce brevetoxins that bioaccumulate and aerosolize, causing neurologic toxicity in ...

Proteomics is emerging as a promising approach for identifying autism biomarkers by detecting protein-level changes linked to ...

Proteomics is the large-scale study of proteins, particularly their structures and functions. It involves the systematic identification, quantification, and analysis of the entire protein complement ...